Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sontakke, Anil
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Terminated	3	409	Europe, US, RoW	Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo	Dompé Farmaceutici S.p.A	Infectious Pneumonia, Severe COVID-19	09/24	09/24
NCT04533022 / 2020-000822-24: Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF May 2023 - May 2023 : Safety and efficacy of AIR study in idiopathic pulmonary fibrosis Interim data from AIR STUDY for IPF Nov 2022 - Nov 2022: Interim data from AIR STUDY for IPF Interim data from AIR STUDY for IPF Feb 2022 - Feb 2022: Interim data from AIR STUDY for IPF	Completed	2	52	Europe, RoW	C21, Buloxibutid, Compound 21	Vicore Pharma AB, Orphan Reach Ltd.	Idiopathic Pulmonary Fibrosis	03/24	03/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sontakke, Anil
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Terminated	3	409	Europe, US, RoW	Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo	Dompé Farmaceutici S.p.A	Infectious Pneumonia, Severe COVID-19	09/24	09/24
NCT04533022 / 2020-000822-24: Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF May 2023 - May 2023 : Safety and efficacy of AIR study in idiopathic pulmonary fibrosis Interim data from AIR STUDY for IPF Nov 2022 - Nov 2022: Interim data from AIR STUDY for IPF Interim data from AIR STUDY for IPF Feb 2022 - Feb 2022: Interim data from AIR STUDY for IPF	Completed	2	52	Europe, RoW	C21, Buloxibutid, Compound 21	Vicore Pharma AB, Orphan Reach Ltd.	Idiopathic Pulmonary Fibrosis	03/24	03/24